Clinical Trial

Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Randomized, Double-Blind, Placebo-Controlled Study designed to assess safety, tolerability, and efficacy of NM8074 in AAV patients when used in combination with Standard of Care (SOC) cyclophosphamide/azathioprine or rituximab plus corticosteroids.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-18; most recent amendment 2025-03-06.
Trial Details
NCT Number NCT06226662
Lead Sponsor NovelMed Therapeutics
Conditions Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Enrollment 12 participants
Start Date 2026-06
Primary Completion 2027-10 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2025-03-11